These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 20404376)

  • 1. Dabigatran was noninferior to warfarin for preventing recurrent venous thromboembolism.
    Gandara E
    Ann Intern Med; 2010 Apr; 152(8):JC4-7. PubMed ID: 20404376
    [No Abstract]   [Full Text] [Related]  

  • 2. Dabigatran etexilate: the first oral anticoagulant available in the United States since warfarin.
    Tran A; Cheng-Lai A
    Cardiol Rev; 2011; 19(3):154-61. PubMed ID: 21464643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dabigatran etexilate: advances in anticoagulation therapy.
    Dahl OE; Huisman MV
    Expert Rev Cardiovasc Ther; 2010 Jun; 8(6):771-4. PubMed ID: 20528634
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic disorders.
    Cheng JW; Vu H
    Clin Ther; 2012 Apr; 34(4):766-87. PubMed ID: 22444784
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism.
    Ridker PM; Goldhaber SZ; Danielson E; Rosenberg Y; Eby CS; Deitcher SR; Cushman M; Moll S; Kessler CM; Elliott CG; Paulson R; Wong T; Bauer KA; Schwartz BA; Miletich JP; Bounameaux H; Glynn RJ;
    N Engl J Med; 2003 Apr; 348(15):1425-34. PubMed ID: 12601075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dabigatran: a new option for anticoagulation in atrial fibrillation and venous thromboembolism.
    Acharjee S; Cannon CP
    Crit Pathw Cardiol; 2011 Jun; 10(2):84-6. PubMed ID: 21988948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dabigatran: a review of clinical and pharmacoeconomic evidence.
    Reddy P; Atay JK; Selbovitz LG; Connors JM; Piazza G; Block CC; Arpino PA; Berliner N; Hutter AM; Fischer MA; Kuter D; Weitzman J; Sherwood GK; Almozlino A; Giugliano RP
    Crit Pathw Cardiol; 2011 Sep; 10(3):117-27. PubMed ID: 21989032
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of venous thromboembolism with dabigatran.
    Schulman S
    Curr Opin Pulm Med; 2012 Sep; 18(5):410-5. PubMed ID: 22617811
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct thrombin inhibitors for the treatment of venous thromboembolism: analysis of the Dabigatran versus Warfarin clinical trial.
    Liem TK; Deloughery TG
    Semin Vasc Surg; 2011 Sep; 24(3):157-61. PubMed ID: 22153026
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial).
    Prandoni P; Taher A
    Expert Opin Pharmacother; 2010 Apr; 11(6):1035-7. PubMed ID: 20307227
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dabigatran etexilate versus warfarin as the oral anticoagulant of choice? A review of clinical data.
    Ma TK; Yan BP; Lam YY
    Pharmacol Ther; 2011 Feb; 129(2):185-94. PubMed ID: 20920530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism.
    Kearon C; Gent M; Hirsh J; Weitz J; Kovacs MJ; Anderson DR; Turpie AG; Green D; Ginsberg JS; Wells P; MacKinnon B; Julian JA
    N Engl J Med; 1999 Mar; 340(12):901-7. PubMed ID: 10089183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dabigatran versus warfarin for venous thromboembolism.
    Teachey DT
    N Engl J Med; 2010 Mar; 362(11):1050; author reply 1050-1. PubMed ID: 20301800
    [No Abstract]   [Full Text] [Related]  

  • 14. Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal.
    Stevenson M; Scope A; Holmes M; Rees A; Kaltenthaler E
    Health Technol Assess; 2009 Oct; 13 Suppl 3():43-8. PubMed ID: 19846028
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial.
    Healey JS; Eikelboom J; Douketis J; Wallentin L; Oldgren J; Yang S; Themeles E; Heidbuchel H; Avezum A; Reilly P; Connolly SJ; Yusuf S; Ezekowitz M;
    Circulation; 2012 Jul; 126(3):343-8. PubMed ID: 22700854
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dabigatran for the prevention of thromboembolic complications in the elderly: a RE-LY-able alternative to warfarin?
    Hughes PJ; Freeman MK
    Consult Pharm; 2012 Jun; 27(6):445-52. PubMed ID: 22698551
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dabigatran etexilate: a novel oral thrombin inhibitor for thromboembolic disease.
    Bovio JA; Smith SM; Gums JG
    Ann Pharmacother; 2011 May; 45(5):603-14. PubMed ID: 21540406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dabigatran versus warfarin for venous thromboembolism.
    Peetz D; Lackner KJ
    N Engl J Med; 2010 Mar; 362(11):1050; author reply 1050-1. PubMed ID: 20237354
    [No Abstract]   [Full Text] [Related]  

  • 19. A comparison of dabigatran etexilate with warfarin in patients with mechanical heart valves: THE Randomized, phase II study to evaluate the safety and pharmacokinetics of oral dabigatran etexilate in patients after heart valve replacement (RE-ALIGN).
    Van de Werf F; Brueckmann M; Connolly SJ; Friedman J; Granger CB; Härtter S; Harper R; Kappetein AP; Lehr T; Mack MJ; Noack H; Eikelboom JW
    Am Heart J; 2012 Jun; 163(6):931-937.e1. PubMed ID: 22709744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hospital budget implications of substituting dabigatran for warfarin in an anticoagulation service.
    Atay JK; Fiumara K; Piazza G; Fanikos J; Goldhaber SZ
    Clin Appl Thromb Hemost; 2012; 18(2):181-4. PubMed ID: 21873358
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.